TABLE OF CONTENTS
1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.3 OVERVIEW OF THE EUROPE N95 MASK MARKET 40
1.4 LIMITATION 42
1.5 MARKETS COVERED 42
2 MARKET SEGMENTATION 46
2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 CURRENCY AND PRICING 48
2.5 DBMR TRIPOD DATA VALIDATION MODEL 49
2.6 MULTIVARIATE MODELLING 52
2.7 PRODUCT SEGMENT LIFELINE CURVE 52
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.9 DBMR MARKET POSITION GRID 54
2.10 MARKET APPLICATION COVERAGE GRID 55
2.11 VENDOR SHARE ANALYSIS 56
2.12 SECONDARY SOURCES 57
2.13 ASSUMPTIONS 57
3 EXECUTIVE SUMMARY 58
3.1 PESTEL ANALYSIS 62
3.2 PORTER'S FIVE FORCES MODEL 63
4 INDUSTRY INSIGHTS 64
5 EUROPE N95 MASK MARKET: REGULATORY FRAMEWORK 66
6 MARKET OVERVIEW 69
6.1 DRIVERS 71
6.1.1 INCREASE IN AIR POLLUTION LEVELS 71
6.1.2 RISING PREVALENCE OF RESPIRATORY DISEASES 72
6.1.3 MANDATORY OCCUPATIONAL SAFETY REGULATIONS FOR WORKERS IN VARIOUS INDUSTRY 72
6.1.4 INCREASED AWARENESS ABOUT THE SIGNIFICANT BENEFITS OF THE N95 MASK 74
6.2 RESTRAINTS 75
6.2.1 ENVIRONMENTAL CONCERNS ASSOCIATED WITH THE DISPOSAL OF N95 MASKS 75
6.2.2 INCREASED USE OF HOMEMADE MASK 76
6.3 OPPORTUNITIES 76
6.3.1 TECHNOLOGICAL ADVANCEMENT PROMOTING THE MANUFACTURING OF ECO-FRIENDLY N95 MASKS 76
6.3.2 RISING HEALTH AND SAFETY CONCERNS AGAINST INFECTIOUS DISEASES AMONG THE CONSUMERS 77
6.3.3 SIGNIFICANT RISE IN THE USE OF N95 MASKS IN THE HEALTHCARE INDUSTRY 78
6.4 CHALLENGES 79
6.4.1 LIMITED PRODUCTION CAPACITY AND MACHINERY FOR MEETING THE DESIRED QUALITY OF N95 MASKS 79
6.4.2 PHYSIOLOGICAL EFFECTS ASSOCIATED WITH THE PROLONGED USE OF N95 MASKS 80
7 EUROPE N95 MASK MARKET, BY PRODUCT 81
7.1 OVERVIEW 82
7.2 STANDARD N95 MASKS 85
7.2.1 BY VALVES 86
7.2.1.1 WITHOUT VALVE 86
7.2.1.2 WITH VALVE 86
7.2.2 BY STYLE 86
7.2.2.1 MOLDED CUP 86
7.2.2.2 FLAT FOLD 86
7.3 SURGICAL N95 MASKS 87
7.3.1 BY VALVES 87
7.3.1.1 WITHOUT VALVE 88
7.3.1.2 WITH VALVE 88
7.3.2 BY STYLE 88
7.3.2.1 MOLDED CUP 88
7.3.2.2 FLAT FOLD 88
8 EUROPE N95 MASK MARKET, BY APPLICATION 89
8.1 OVERVIEW 90
8.2 INFECTIOUS DISEASES 93
8.2.1 VIRUSES 94
8.2.2 BACTERIA 94
8.2.3 FUNGI 94
8.2.4 PARASITES 94
8.2.5 OTHERS 94
8.3 RESPIRATORY SAFETY 94
8.3.1 DUSTS 95
8.3.2 FUMES 95
8.3.3 MISTS 96
8.3.4 FOG 96
8.3.5 SPRAYS 96
8.3.6 SMOKES 96
8.3.7 GASES 96
8.3.8 VAPORS 96
8.3.9 OTHERS 96
8.4 ALLERGIES 96
8.4.1 POLLENS 97
8.4.2 DUST MITES 97
8.4.3 PARTICULATES 97
8.4.4 PET ALLERGENS 97
8.4.5 OTHERS 98
8.5 SURGERIES 98
9 EUROPE N95 MASK MARKET, BY TYPE OF MATERIAL 99
9.1 OVERVIEW 100
9.2 POLYPROPYLENE (PP) 103
9.3 POLYURETHANE 103
9.4 POLYESTER 104
9.5 COTTON 105
10 EUROPE N95 MASK MARKET, BY USABILITY 106
10.1 OVERVIEW 107
10.2 DISPOSABLE 110
10.3 REUSABLE 111
11 EUROPE N95 MASK MARKET, BY SIZE 112
11.1 OVERVIEW 113
11.2 STANDARD SIZE 116
11.3 SMALL SIZE 116
11.4 OTHERS 117
12 EUROPE N95 MASK MARKET, BY END USER 118
12.1 OVERVIEW 119
12.2 HOSPITALS 122
12.2.1 LONG-TERM CARE HOSPITALS 123
12.2.2 ACUTE CARE HOSPITALS 123
12.2.3 NURSING FACILITIES 123
12.2.4 REHABILITATION CENTERS 123
12.3 CLINICS 123
12.4 AMBULATORY SURGICAL CENTERS 124
12.5 DIAGNOSTIC LABORATORIES 124
12.6 PUBLIC SAFETY SERVICE ORGANIZATION 125
12.7 CONSTRUCTION COMPANIES 126
12.8 MANUFACTURING COMPANIES 127
12.9 OIL & GAS COMPANIES 128
12.10 INDIVIDUAL 128
12.11 OTHERS 129
13 EUROPE N95 MASK MARKET, BY DISTRIBUTION CHANNEL 130
13.1 OVERVIEW 131
13.2 ONLINE SALES 134
13.2.1 ONLINE PHARMACIES 135
13.2.2 OTHERS 135
13.3 OFFLINE SALES 135
13.3.1 HOSPITAL PHARMACIES 136
13.3.2 SUPERMARKET/HYPERMARKET 136
13.3.3 DRUG STORE 136
13.3.4 RETAIL PHARMACIES 136
14 EUROPE N95 MASK MARKET, BY REGION 137
14.1 EUROPE 138
14.1.1 GERMANY 149
14.1.2 U.K. 156
14.1.3 FRANCE 162
14.1.4 ITALY 169
14.1.5 SPAIN 175
14.1.6 BELGIUM 181
14.1.7 RUSSIA 188
14.1.8 NETHERLANDS 195
14.1.9 SWITZERLAND 202
14.1.10 TURKEY 208
14.1.11 REST OF EUROPE 215
15 EUROPE N95 MASK MARKET, COMPANY LANDSCAPE 216
15.1 COMPANY SHARE ANALYSIS: EUROPE 216
16 SWOT ANALYSIS 217
17 COMPANY PROFILE 218
17.1 3M 218
17.1.1 COMPANY SNAPSHOT 218
17.1.2 REVENUE ANALYSIS 218
17.1.3 COMPANY SHARE ANALYSIS 219
17.1.4 PRODUCT PORTFOLIO 219
17.1.5 RECENT DEVELOPMENT 219
17.2 HONEYWELL INTERNATIONAL INC. 220
17.2.1 COMPANY SNAPSHOT 220
17.2.2 REVENUE ANALYSIS 220
17.2.3 COMPANY SHARE ANALYSIS 221
17.2.4 PRODUCT PORTFOLIO 221
17.2.5 RECENT DEVELOPMENT 221
17.3 KIMBERLY-CLARK 222
17.3.1 COMPANY SNAPSHOT 222
17.3.2 REVENUE ANALYSIS 222
17.3.3 COMPANY SHARE ANALYSIS 223
17.3.4 PRODUCT PORTFOLIO 223
17.3.5 RECENT DEVELOPMENT 223
17.4 CARDINAL HEALTH 224
17.4.1 COMPANY SNAPSHOT 224
17.4.2 REVENUE ANALYSIS 224
17.4.3 COMPANY SHARE ANALYSIS 225
17.4.4 PRODUCT PORTFOLIO 225
17.4.5 RECENT DEVELOPMENT 225
17.5 OWENS & MINOR 226
17.5.1 COMPANY SNAPSHOT 226
17.5.2 REVENUE ANALYSIS 226
17.5.3 COMPANY SHARE ANALYSIS 227
17.5.4 PRODUCT PORTFOLIO 227
17.5.5 RECENT DEVELOPMENT 227
17.6 ALPHAPROTECH 228
17.6.1 COMPANY SNAPSHOT 228
17.6.2 REVENUE ANALYSIS 228
17.6.3 PRODUCT PORTFOLIO 229
17.6.4 RECENT DEVELOPMENT 229
17.7 MAKRITE 230
17.7.1 COMPANY SNAPSHOT 230
17.7.2 PRODUCT PORTFOLIO 230
17.7.3 RECENT DEVELOPMENT 230
17.8 MEDLINE INDUSTRIES, LP 231
17.8.1 COMPANY SNAPSHOT 231
17.8.2 PRODUCT PORTFOLIO 231
17.8.3 RECENT DEVELOPMENT 231
17.9 MOLDEX-METRIC 232
17.9.1 COMPANY SNAPSHOT 232
17.9.2 PRODUCT PORTFOLIO 232
17.9.3 RECENT DEVELOPMENT 233
17.10 PRESTIGE AMRITECH 234
17.10.1 COMPANY SNAPSHOT 234
17.10.2 PRODUCT PORTFOLIO 234
17.10.3 RECENT DEVELOPMENT 234
17.11 THE GERSON COMPANY 235
17.11.1 COMPANY SNAPSHOT 235
17.11.2 PRODUCT PORTFOLIO 235
17.11.3 RECENT DEVELOPMENT 235
18 QUESTIONNAIRE 236
19 RELATED REPORTS 240

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.